Literature DB >> 21625241

Spinal cord injury sequelae alter drug pharmacokinetics: an overview.

H Mestre1, T Alkon, S Salazar, A Ibarra.   

Abstract

STUDY
DESIGN: Literature review.
OBJECTIVES: Critical review of the literature published on the physiological alterations caused by spinal cord injury (SCI) and their effect on the pharmacokinetic parameters of commonly employed drugs. The review introduces the most recent treatment protocols of a variety of drugs, enabling the modern clinician to apply efficacious and cost-effective solutions to the pharmacological treatment of SCI patients.
METHODS: Studies published in international indexed journals up to January 2011 were selected from the PubMed database.
RESULTS: The review evaluated the sequelae of SCI and their effect on pharmacological processes. The results demonstrated that these alterations affected the pharmacokinetics of drugs commonly administered to SCI patients, such as antibiotics, muscle relaxants, immunosuppressants and analgesics.
CONCLUSION: There are multiple etiologies to SCI and patients present with varying degrees of impairment. Factors such as level of injury and completeness of the injury create a very heterogeneous population within the SCI community. The heterogeneity of this population creates a problem when trying to standardize pharmacokinetic (PK) parameters. It is because of this that specific physiological alterations must be linked to changes in PK and be identified within the clinical setting. This relationship between physiology and PK enables the clinician to be alert for possible pharmacological complications in individual patients based on their clinical manifestations. Future research should aim to develop rigorous therapeutic guidelines tailored to the diverse manifestations of SCI so as to provide effective, affordable and safe pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625241     DOI: 10.1038/sc.2011.58

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  6 in total

1.  Medication profile and polypharmacy in adults with pediatric-onset spinal cord injury.

Authors:  M Hwang; K Zebracki; L C Vogel
Journal:  Spinal Cord       Date:  2015-04-21       Impact factor: 2.772

2.  A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.

Authors:  Robert G Grossman; Michael G Fehlings; Ralph F Frankowski; Keith D Burau; Diana S L Chow; Charles Tator; Angela Teng; Elizabeth G Toups; James S Harrop; Bizhan Aarabi; Christopher I Shaffrey; Michele M Johnson; Susan J Harkema; Maxwell Boakye; James D Guest; Jefferson R Wilson
Journal:  J Neurotrauma       Date:  2013-10-11       Impact factor: 5.269

Review 3.  Spinal cord injury pharmacotherapy: Current research & development and competitive commercial landscape as of 2015.

Authors:  Jason R Guercio; Jason E Kralic; Eric J Marrotte; Michael L James
Journal:  J Spinal Cord Med       Date:  2018-02-27       Impact factor: 1.985

4.  The risks of polypharmacy following spinal cord injury.

Authors:  Patrick Kitzman; Darrin Cecil; Jimmi Hatton Kolpek
Journal:  J Spinal Cord Med       Date:  2016-03-09       Impact factor: 1.985

5.  Prescription drug claims following a traumatic spinal cord injury for older adults: a retrospective population-based study in Ontario, Canada.

Authors:  Sara J T Guilcher; Mary-Ellen Hogan; Andrew Calzavara; Sander L Hitzig; Tejal Patel; Tanya Packer; Aisha K Lofters
Journal:  Spinal Cord       Date:  2018-07-31       Impact factor: 2.772

6.  Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.

Authors:  Ashley Nguyen; Diana S-L Chow; Lei Wu; Yang Angela Teng; Mahua Sarkar; Elizabeth G Toups; James S Harrop; Karl M Schmitt; Michele M Johnson; James D Guest; Bizhan Aarabi; Christopher I Shaffrey; Maxwell Boakye; Ralph F Frankowski; Michael G Fehlings; Robert G Grossman
Journal:  J Clin Pharmacol       Date:  2021-07-09       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.